Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PROK
STRONG SELLREMOVEProKidney Corp. · Healthcare · United States · $547M · Avg Vol: $2M/d
Early-stage clinical biotech company with high cash burn and no commercialized products, failing both the Buffett and Terry Smith quality criteria.
COMPANY DESCRIPTION
ProKidney Corp. is a clinical-stage biotechnology company developing an autologous cell therapy product, Renal Autologous Cell Therapy (REACT®), for chronic kidney disease (CKD). The company's innovative approach utilizes a patient's own renal cells to slow or reverse the progression of CKD. Its competitive advantage lies in its proprietary cell therapy platform and its potential to offer a disease-modifying treatment in a large, underserved patient population.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 76,000 | 893,000 | 1075.0% |
| EPS | -0.23 | -0.57 | -0.62 | -0.52 | — |
| Shares | 62M | 60M | 128M | 142M | +130.4% |
| Debt | 2M | 4M | 3M | 4M | 18.9% |
| Equity | -1.1B | -1.1B | -995M | -1.0B | — |
| Op CF | -77M | -90M | -126M | -120M | — |
| Inv CF | -2M | -330M | 20M | 104M | — |
| Fin CF | 549M | -10M | 144M | 26M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PROK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PROK | ProKidney Corp.(you) | $547M | 11 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $552M | 10 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $526M | 10 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $558M | 13 | STRONG SELL |
| ARVN | Arvinas, Inc. | $570M | 14 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $454M | 13 | STRONG SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $708M | 12 | STRONG SELL |
| SGP | SpyGlass Pharma, Inc. | $663M | 14 | STRONG SELL |
| ALT | Altimmune, Inc. | $597M | 6 | STRONG SELL |
| OCGN | Ocugen, Inc. | $477M | 7 | STRONG SELL |
Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%